Sept 4 (Reuters) - Prescient Therapeutics Ltd PTX.AX
* U.S. FDA has lifted clinical hold on co's phase 1b/2 clinical trial of PTX-200 in patients with refractory or relapsed acute myeloid leukemia
Sept 4 (Reuters) - Prescient Therapeutics Ltd PTX.AX
* U.S. FDA has lifted clinical hold on co's phase 1b/2 clinical trial of PTX-200 in patients with refractory or relapsed acute myeloid leukemia